DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Volociximab
Volociximab
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
WO 2015/123595 Al 20 August 2015 (20.08.2015) P O P C T
The Two Tontti Tudiul Lui Hi Ha Unit
W W W .Bio Visio N .Co M
The Constituents and Potential Targets Of
Integrins As Therapeutic Targets: Successes and Cancers
Ep 3321281 A1
Integrin Alpha5 in Human Breast Cancer Is a Mediator of Bone Metastasis and a Therapeutic Target for the Treatment of Osteolytic Lesions
INN Working Document 05.179 Update 2011
(12) Patent Application Publication (10) Pub. No.: US 2007/0258889 A1 Douglas Et Al
(INN) for Biological and Biotechnological Substances
Biosimilar Antibodies & ELISA Kits
SN12C Xenograft Model for Renal Cancer
B1-Integrin: a Potential Therapeutic Target in the Battle Against Cancer Recurrence
Bone Metastasis from Renal Cell Carcinoma
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Volociximab, a Chimeric Monoclonal Antibody That Specifically
Biovision 11/17 for Research Use Only
Top View
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Integrins As Therapeutic Targets: Successes and Cancers
Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
A Novel Small-Molecule Integrin Antagonist Inhibits Cells Adhesion Followed by Anoikis in Endothelial Cells - a Comparative Analysis with Cilengitide
Antibody Therapy of Cancer
The Emerging Role of Anti-Angiogenic Therapy in Ovarian Cancer (Review)
A1092-Anti-Alpha 5 Beta 1 Integrin (Volociximab)
Antiangiogenic Therapy for Advanced Renal Cell Carcinoma T: 617.576.5708 F: 617.576.5808 Edited by Gary Hudes, M.D., Brian Rini, M.D
Pharmacological and Clinical Importance of Integrin Antagonists
Engineered Fc Regions for Site-Specific Conjugation
Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
(INN) for Biological and Biotechnological Substances
Theranostics 2011, 1 154
Integrin Alpha5 in Human Breast Cancer Is A
Retina Pipeline 2021
Ep 3088005 A1
Antiangiogenesis Therapy: an Update After the First Decade
Assessment of the Evolution of Cancer Treatment Therapies
WO 2015/038818 A2 19 March 2015 (19.03.2015) P O P C T
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic
Assessment of the Evolution of Cancer Treatment Therapies
Β1 and Β3 Integrins in Breast, Prostate and Pancreatic Cancer: a Novel Implication (Review)
WO 2016/059622 A2 21 April 2016 (21.04.2016) P O P C T
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al
Potential of Integrin Inhibitors for Treating Ovarian Cancer: a Literature Review